Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
This protein carries a polyhistidine tag at the N-terminus
The protein has a calculated MW of 22.4 kDa. The protein migrates as 27-35 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human TNFSF11 Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
The purity of Human TNFSF11 Protein, His Tag (Cat. No. RAL-H5240) is more than 85% and the molecular weight of this protein is around 80-100 kDa verified by SEC-MALS.
Immobilized Human RANK Protein, Mouse IgG2a Fc Tag (Cat. No. RAK-H5251) at 0.5 μg/mL (100 μL/well) can bind Human TNFSF11 Protein, His Tag (Cat. No. RAL-H5240) with a linear range of 0.4-6 ng/mL (QC tested).
Immobilized Human OPG, Fc Tag (Cat. No. TNB-H5259) at 2 μg/mL (100 μL/well) can bind Human TNFSF11 Protein, His Tag (Cat. No. RAL-H5240) with a linear range of 0.2-2 ng/mL (Routinely tested).
Anti-TNFSF11 (human IgG1) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human TNFSF11 Protein, His Tag (Cat. No. RAL-H5240) with an affinity constant of 0.274 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Captured Human RANK Protein, Mouse IgG2a Fc Tag (Cat. No. RAK-H5251) on CM5 chip via Anti-Mouse antibodies surface can bind Human TNFSF11 Protein, His Tag (Cat. No. RAL-H5240) with an affinity constant of 0.309 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Loaded Human RANK Protein, Mouse IgG2a Fc Tag (Cat. No. RAK-H5251) on AMC Biosensor, can bind Human TNFSF11 Protein, His Tag (Cat. No. RAL-H5240) with an affinity constant of 0.409 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Loaded Anti-TNFSF11 MAb (human IgG1) on AHC Biosensor, can bind Human TNFSF11 Protein, His Tag (Cat. No. RAL-H5240) with an affinity constant of 0.239 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides innovative solutions for neuroscience research. Recombinant proteins, neural factors, pre-formed fibrils, electrophysiological electrodes, as well as Organoid Toolbox all in Aneuro aiming to advance neuroscience research, develop therapeutic interventions, and improve diagnostic methods for neurological diseases.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Fecha | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Narlumosbart | JMT-103 | Approved | Shanghai Jmt-Bio Inc | 津立生 | Mainland China | Giant Cell Tumor of Bone | Shanghai Jmt-Bio Inc | 2023-09-05 | Solid tumours; Bone metastases; Osteoporosis; Bone Diseases; Osteoporosis, Postmenopausal; Hypercalcemia; Neoplasms; Multiple Myeloma; Giant Cell Tumor of Bone; Glucocorticoid-induced osteoporosis | Details |
Denosumab biosimilar (Mabwell) | 9-MW-0311; 9MW0321; 9-MW0321; 9MW-0321; 9-MW-0321; TK-006; MW-032; MW-031; 9MW0311; 9-MW0311; 9MW-0311 | Approved | Jiangsu T-Mab Bio-Pharmaceuticals Co Ltd | 迈利舒, 迈卫健, MAIWEIJIAN, MAILISHU | Mainland China | Osteoporosis, Postmenopausal | Jiangsu T-Mab Bio-Pharmaceuticals Co Ltd | 2023-03-28 | Bone metastases; Solid tumours; Osteoporosis; Osteoporosis, Postmenopausal; Breast Neoplasms; Giant Cell Tumor of Bone; Bone Neoplasms | Details |
Denosumab biosimilar (Qilu Pharma) | QL-1206 | Approved | Qilu Pharmaceutical Co Ltd | 鲁可欣 | Mainland China | Osteoporosis, Postmenopausal | Qilu Pharmaceutical Co Ltd | 2023-09-28 | Solid tumours; Bone metastases; Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar (Boan Biopharma/Luye) | LY-01011; BA-1102; BA-6101; LY-06006 | Approved | Shandong Boan Biotechnology Co Ltd, Luye Pharma Group Ltd | Mainland China | Osteoporosis, Postmenopausal | Shandong Boan Biotechnology Co Ltd | 2022-11-10 | Bone metastases; Solid tumours; Osteoporosis; Osteoporosis, Postmenopausal; Neoplasms; Multiple Myeloma; Giant Cell Tumor of Bone; Bone Neoplasms; Neoplasm Metastasis | Details | |
Denosumab | NSC-744010; AMG-162 | Approved | Amgen Inc | Prolia, Xgeva, Pralia, Ranmark, 普罗力 | EU | Osteoporosis, Postmenopausal | Amgen Europe Bv | 2010-05-26 | Lymphoma; Multiple Myeloma; Prostatic Neoplasms, Castration-Resistant; Feeding and Eating Disorders; Breast Neoplasms; Prostatic Neoplasms; Giant Cell Tumors; Arthropathy, Neurogenic; Osteogenesis Imperfecta; Osteosarcoma; Giant Cell Tumor of Bone; Breast Diseases; Bone Neoplasms; Fractures, Bone; Bone Cysts, Aneurysmal; Lung Neoplasms; Osteoblastoma; Granuloma, Giant Cell; Thyroid Neoplasms; Lymphoma, Non-Hodgkin; Glucocorticoid-induced osteoporosis; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Fibroma; Crohn Disease; Anorexia Nervosa; Fibrous Dysplasia of Bone; Kidney Neoplasms; Solid tumours; Cataract; Hematologic Neoplasms; Endocrine Gland Neoplasms; Head and Neck Neoplasms; Hematopoietic stem cell transplantation (HSCT); Bone Diseases, Metabolic; Osteoporosis; Carcinoma; Pain; Parathyroid Neoplasms; Bone metastases; Osteoporosis, Postmenopausal; Smoldering Multiple Myeloma; Colonic Neoplasms; Hypercalcemia; Neoplasms; Chondroblastoma; Kidney Diseases; Carcinoma, Ovarian | Details |
Denosumab biosimilar(Reliance Life Sciences) | R-TPR-045 | Approved | Reliance Life Sciences | DenosuRel | India | Osteoporosis, Postmenopausal; Bone metastases | Reliance Life Sciences | 2022-02-01 | Bone metastases; Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar (Sandoz) | GP-2411 | Approved | Novartis Pharma Ag, Sandoz | Jubbonti®, Wyost® | United States | Osteoporosis; Osteoporosis, Postmenopausal; Glucocorticoid-induced osteoporosis | Sandoz Inc, Sandoz | 2024-03-05 | Osteoporosis; Osteoporosis, Postmenopausal; Glucocorticoid-induced osteoporosis | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Denosumab biosimilar (Intas Biopharmaceuticals) | Phase 3 Clinical | Intas Biopharmaceuticals | Osteoporosis, Postmenopausal | Details | |
Denosumab biosimilar(Shanghai Hansoh) | HS-20090; HS-20090-2 | Phase 3 Clinical | Shanghai Hansoh Biomedical Co Ltd, Jiangsu Hansoh Pharmaceutical Group Co Ltd | Bone metastases; Solid tumours; Neoplasms; Osteoporosis, Postmenopausal; Bone Diseases; Hypercalcemia; Multiple Myeloma; Giant Cell Tumor of Bone; Nutritional and Metabolic Diseases | Details |
TVB-009 | TVB-009 | Phase 3 Clinical | Teva Pharmaceutical Industries Ltd | Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar (Henlius ) | HLX-14; HLX14 | Phase 3 Clinical | Shanghai Henlius Biotech Inc | Osteoporosis, Postmenopausal | Details |
CMAB807 | CMAB-807; CMAB807X | Phase 3 Clinical | Shanghai Biomabs Pharmaceuticals Co Ltd, Shanghai Maitai Yabo Biotechnology Co Ltd | Osteoporosis, Postmenopausal | Details |
Recombinant human anti-RANKL momoclonal antibody (Qilu Pharmaceutical) | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Osteoporosis, Postmenopausal; Neoplasms | Details | |
Denosumab biosimilar (AryoGen) | Phase 3 Clinical | Aryogen Biopharma | Osteoporosis | Details | |
Denosumab biosimilar(Curateq Biologics) | BP-16 | Phase 3 Clinical | CuraTeQ Biologics Pvt Ltd | Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar(Enzene Biosciences) | ENZ-215 | Phase 3 Clinical | Enzene Biosciences Ltd | Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar(Alvotech Swiss) | AVT-03 | Phase 3 Clinical | Alvotech Swiss Ag | Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar(Mabxience) | Phase 3 Clinical | Mabxience Sa | Osteoporosis, Postmenopausal | Details | |
Denosumab biosimilar (Hualan Biological Engineering) | Phase 3 Clinical | Hualan Genetic Engineering Co Ltd | Solid tumours; Bone metastases; Osteoporosis, Postmenopausal | Details | |
RGB-14-P | RGB-14-P | Phase 3 Clinical | Gedeon Richter Plc | Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar(Fresenius Kabi) | FKS-518 | Phase 3 Clinical | Fresenius Kabi Swissbiosim Gmbh | Osteoporosis, Postmenopausal | Details |
Denosumab biosimilar (Samsung Bioepis) | SB-16 | Phase 3 Clinical | Samsung Bioepis Co Ltd | Osteoporosis, Postmenopausal | Details |
Denosumab biosimiliar (Celltrion) | CT-P41 | Phase 3 Clinical | Celltrion Inc | Osteoporosis, Postmenopausal | Details |
KP-46 | KP-46; FFC-11; LX-001; AP-002 | Phase 2 Clinical | University Of Heidelberg, Meram | Solid tumours | Details |
LZM-004 | LZM-004 | Phase 1 Clinical | Livzon(Group) Pharmaceutical Factory | Bone metastases | Details |
Recombinant human anti-RANKL antibody (Innovent Biologics) | IBI-307 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd | Osteoporosis | Details |
GB-223 | GB-223 | Phase 1 Clinical | Genor Biopharma Co Ltd | Solid tumours; Bone metastases; Osteoporosis, Postmenopausal; Bone Neoplasms; Giant Cell Tumor of Bone | Details |
MV-088 | MV-088 | Phase 1 Clinical | Kpc Pharmaceuticals Inc | Osteoporosis, Postmenopausal | Details |
Recombinant anti-RANKL monoclonal antibody(Jiangsu Pacific-Meinuoke) | Phase 1 Clinical | Jiangsu Pacific-Meinuoke Bio-Pharmaceutical Co Ltd | Osteoporosis, Postmenopausal | Details | |
Recombinant human anti-RANKL antibody (Hisun Pharma) | HS629 | Phase 1 Clinical | Zhejiang Hisun Pharmaceutical Co Ltd | Bone metastases; Solid tumours | Details |
This web search service is supported by Google Inc.